Cash from Operations (TTM) Chart

View Cash from Operations (TTM) for RZLT.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (TTM) Chart
Start Trial

Historical Cash from Operations (TTM) Data

View and export this data back to 2013. Start Trial.
Date Value
March 31, 2026 -73.48M
December 31, 2025 -77.15M
September 30, 2025 -70.49M
June 30, 2025 -69.08M
March 31, 2025 -65.60M
December 31, 2024 -63.44M
September 30, 2024 -62.80M
June 30, 2024 -57.37M
March 31, 2024 -50.20M
December 31, 2023 -53.00M
September 30, 2023 -47.48M
June 30, 2023 -44.48M
March 31, 2023 -45.24M
December 31, 2022 -41.16M
September 30, 2022 -40.86M
June 30, 2022 -39.62M
March 31, 2022 -32.66M
December 31, 2021 -24.16M
September 30, 2021 -23.23M
June 30, 2021 -20.44M
March 31, 2021 -19.36M
December 31, 2020 -19.57M
September 30, 2020 -18.79M
June 30, 2020 -24.17M
March 31, 2020 -23.85M
Date Value
December 31, 2019 -26.63M
September 30, 2019 -22.80M
June 30, 2019 -15.30M
March 31, 2019 -15.42M
December 31, 2018 -9.143M
September 30, 2018 -10.64M
June 30, 2018 -14.11M
March 31, 2018 -13.87M
December 31, 2017 -15.31M
September 30, 2017 -15.25M
June 30, 2017 -13.31M
March 31, 2017 -12.82M
December 31, 2016 -11.75M
September 30, 2016 -10.94M
June 30, 2016 -10.49M
March 31, 2016 -9.300M
December 31, 2015 -8.669M
September 30, 2015 -8.124M
June 30, 2015 -7.079M
March 31, 2015 -7.214M
December 31, 2014 -6.014M
September 30, 2014 -4.640M
June 30, 2014 -3.167M
March 31, 2014 -1.302M
December 31, 2013 -1.969M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (TTM) Range, Past 5 Years

View Cash from Operations (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (TTM) Benchmarks

View Cash from Operations (TTM) Benchmarks
Start Trial
SELLAS Life Sciences Group, Inc. -28.42M
AbbVie, Inc. 19.51B
Marker Therapeutics, Inc. -9.756M
Avalo Therapeutics, Inc. -68.29M
Krystal Biotech, Inc. 272.34M